CG Invites' personalized cancer vaccine shows promise

CG Invites Demonstrates Potent Immunological Response and Antineoplastic Efficacy of AI-Powered Personalized Cancer Vaccine

Achieves 2.8-fold Superior Immunogenic Response Compared to Industry Leaders with Confirmed Tumor Suppression: "Advancing Toward a New Frontier in Cancer Therapeutics"

CG Invites (Co-CEOs Chung In-chul and Oh Su-yeon), a frontrunner in digital genomics-driven drug development, announced groundbreaking preclinical results for their personalized cancer immunotherapy vaccine on the 11th.

 

Cancer vaccines epitomize personalized medicine, harnessing tumor-specific antigens to activate the patient's immune system for targeted malignant cell elimination.

 

With their exceptional safety profile and minimal adverse effects, these immunotherapeutics are positioned as leading candidates for next-generation cancer treatment.

 

The field has garnered global attention following Moderna's encouraging clinical outcomes for their melanoma vaccine, presented at the American Society of Clinical Oncology (ASCO 2024).

 

CG Invites' Personalized Cancer Vaccine: Activating the Body's Natural Defense System The therapeutic mechanism of cancer vaccines parallels the body's intrinsic immune response pathways.

 

Analogous to how influenza vaccines prime immune responses through viral antigen presentation, cancer vaccines stimulate anti-tumor immunity by exposing immune cells to tumor-specific neoantigens.

 

However, cancer vaccines distinguish themselves through their dual mechanism of action: therapeutic intervention against existing malignancies and prophylactic protection against disease recurrence.

 

Immune cells "programmed" to recognize tumor-specific signatures acquire targeted cytotoxic capabilities against malignant cells, generating robust antineoplastic responses while establishing durable immunological memory for recurrence prevention.

 

The inherent heterogeneity of tumor mutations across patients necessitates individualized vaccine formulations, distinguishing these immunotherapeutics from conventional vaccines.

 

Breakthrough anti-cancer effect demonstrated in mouse model of colon cancer In this preclinical investigation, CG Invites employed their proprietary imNEO algorithm to design cancer vaccines for colorectal carcinoma murine models.

 

The study demonstrated significant immunogenic responses in 19 of 25 neoantigens (76% response rate).

 

This represents a 2.8-fold enhancement over current industry benchmarks (approximately 20%) established by global leaders.

 

CG Invites also conducted tumor growth inhibition tests by stratifying 25 tumor-specific neoantigens into 5 distinct groups.

 

Results demonstrated complete tumor stasis in two groups and partial growth suppression in the other two groups.

 

These findings validate the therapeutic efficacy of CG Invites' identified tumor-specific neoantigens in mediating tumor growth inhibition.

 

Future combinatorial application of all 25 neoantigens is anticipated to yield enhanced anti-tumor efficacy.

 

Figure.

 

Immunogenicity and tumor growth inhibition test results using the mouse colorectal cancer model (MC38).

AI-Derived Tumor Signatures: The imNEO Algorithm imNEO, developed by CG Invites, is an AI-powered algorithmic platform for precise identification of tumor-specific molecular signatures.

 

This technology integrates 30 distinct immunological parameters, demonstrating unprecedented accuracy across multiple malignancies, including melanoma, lung cancer, colorectal adenocarcinoma, gastric cancer and pancreatic cancer.

 

These findings transcend mere technical validation, demonstrating effective mobilization of patient immunological responses.

 

This advancement shows promise either as a combined therapy to existing oncological treatments or as a novel therapeutic modality.

 

“Personalized anti-cancer vaccine could be a game-changer in cancer treatment,” said experts Experts also predict that anti-cancer vaccines will revolutionize cancer treatment.

 

Prof.

 

Byoung-chul Cho of the Sinchon Severance Lung Cancer Center evaluated, who developed the global blockbuster Korean drug LECLAZA®, "While interpatient and intertumoral heterogeneity has presented significant therapeutic challenges, personalized cancer vaccines represent a paradigm-shifting therapeutic modality that transcends the limitations of conventional antineoplastic agents.

 

This breakthrough offers renewed hope for both oncology patients and clinical practitioners." Prof.

 

Bhak Jong-hwa of UNIST remarked, "In an era where clinical translation of genomic research remains exceptionally rare, CG Invites' cancer vaccine algorithm represents a landmark achievement, validating the therapeutic utility of genomic research." CEO Chung In-chul emphasized, "These results definitively demonstrate the potential of personalized cancer vaccines to pioneer novel pathways in oncological intervention." He further noted, "We are achieving significant advances in essential mRNA platform development and biomolecular delivery systems.

 

We anticipate completing preclinical studies and initiating human clinical trials in the near term."